Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS

Great characterization of another long term toxicity after CAR-T for myeloma. UCSF Helen Diller Family Comprehensive Cancer Ctr

Just in time for #ISHL13 a comprehensive review on Hodgkin lymphoma biology and implications for translational research is now available Trends in Molecular Medicine, masterfully authored by Ralf Küppers Uni Duisburg-Essen @unidue.bsky.social #SFB1530 cell.com/trends/molecul…

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation ashpublications.org/blood/article/…

ENRICH Primary analysis 4y fup R-Ibrutinib vs R-chemo (BR or RCHOP) 1L #MCL IR superior PFS to ICT HR 0.69 p=0.003 ⬇️ haem tox Earlier ⬆️QoL with R-Ibr Major benefit seen vs RCHOP subgrp 1st 1L RCT across any lymphoma (not incl CLL) showing non-chemo superior to ICT #ASH2024

Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/article/…

👀👀👀

Excited to share the stage with Drs. Nathan Fowler and Paolo Strati at the Satellite Symposium during #ASH24!Don’t miss it—sign up now to join the discussion! #LymphomaResearch CU Anschutz Lymphoma Program CU Anschutz Division of Hematology University of Colorado Anschutz ASH

Very excited to share our work led by Emily Liang just published in Blood Advances! doi.org/10.1182/blooda… We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients. Models performed well in our independent

Next up, CD22-CAR T from Stanford Medicine 3 year follow up, 37/38 prior CR19 CAR T Durable responses in one third of patients Higher rates of SPMs - ?impact of 2x rounds of lymphodepletion Good to see many presenters reporting NRM #ASH24 #lymsm #TCellRx Ash Alizadeh, MD/PhD 🇺🇸

ENRICH: ibrutinib+R vs BR or RCHOP IR better PFS than RCHOP but *not* better than BR Reasonable to consider BTKi first line in patient who prefers to avoid benda but I suspect unlikely to be cost effective given continuous therapy #ASH24 #lymsm

Retrospective maint R TRIANGLE #ASH24 - propensity scoring: PFS superior with RM - benefit of RM across all arms for PFS - no diff in OS - MV for p53: PFS benefit still seen - more infx with RM across all arms (none G5) BTKi + R maintenance for 1L MCL after induction. #lymsm

Just out! Excited about our Journal of Clinical Oncology manuscript published concurrently with our #ASH24 presentation. Fred Hutch Cancer Center #CLL Zanubrutinib vs. BR in Patients with TN CLL/SLL: Median 5-Year Follow-Up of SEQUOIA | Journal of Clinical Oncology ascopubs.org/doi/10.1200/jc…

Check out Dr Seshadri and my editorial on bridging therapy before CART —Bridging the Gap: Treatment Before CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma dailynews.ascopubs.org/do/bridging-ga…

👏 Tour de force analysis of SSQ-MM, a PRO measure focused on dexamethasone in myeloma #MMsm 100s of pts filled this out: common steroid AEs include insomnia but also prox myopathy (difficulty rising from 🪑). ⬆️ SSQ-MM strongly assoc with ⬇️ QOL. Time for #downwithdex!

#Hematology Immunological consequences of #CARTcell therapy: an analysis of infectious complications and immune reconstitution | ⁦Blood Advances⁩ | American Society of Hematology #lymsm ashpublications.org/bloodadvances/…

Tough real world outcomes for bispecifics.

New paper in BMJ (Research Methods & Reporting): “Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide” led by Pedro Lopez-Ayala & Tobias Zimmermann with Gary Collins & myself bmj.com/content/390/bm…

Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy astctjournal.org/article/S2666-… Mehdi Hamadani, MD Mazyar Shadman, MD MPH